Display options
Cite
Fountzilas C, Bajor DL, Mukherjee S, et al. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-1650.
Fountzilas, C., Bajor, D. L., Mukherjee, S., Saltzman, J., Witkiewicz, A. K., Maguire, O., Minderman, H., Nambiar, R., Rosenheck, H. R., Knudsen, E. S., Muhitch, J. B., Abrams, S. I., Wang, C., Hutson, A. D., Attwood, K., Hicks, K. A., Jurcevic, J. A., Kalinski, P., Iyer, R., & Boland, P. M. (2021). Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-1650
Fountzilas, Christos, et al. "Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-1650
Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021 Oct 13; doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13. PMID: 34645646.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2021 Oct 13; doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13.

Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Christos Fountzilas, David L Bajor, Sarbajit Mukherjee, Joel Saltzman, Agnieszka K Witkiewicz, Orla Maguire, Hans Minderman, Ram Nambiar, Hanna R Rosenheck, Erik S Knudsen, Jason B Muhitch, Scott I Abrams, Chong Wang, Alan D Hutson, Kristopher Attwood, Karen A Hicks, Jennifer A Jurcevic, Pawel Kalinski, Renuka Iyer, Patrick M Boland

Affiliations

  1. Roswell Park Comprehensive Cancer Center, Buffalo, New York. [email protected].
  2. Case Comprehensive Cancer Center, Cleveland, Ohio.
  3. Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  4. Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

PMID: 34645646 DOI: 10.1158/1078-0432.CCR-21-1650

Abstract

PURPOSE: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with

PATIENTS AND METHODS: In this phase Ib/II study, cetuximab was combined with pembrolizumab in patients with RASwt mCRC with ≥ one prior line of therapy for advanced disease. We analyzed baseline on-treatment tumor tissues for changes in the tumor microenvironment (TME), using flow cytometry and multispectral immunofluorescence.

RESULTS: Forty-four patients were evaluable for efficacy. The study was negative for the primary efficacy endpoint [overall response rate: 2.6%, 6-month progression-free survival (PFS): 31%;

CONCLUSIONS: The combination of cetuximab and pembrolizumab is inactive in patients with RASwt mCRC, despite its partial local immunologic efficacy. Further development of immuno-oncology combinations with enhanced efficacy and/or targeting additional or alternative immune checkpoints merits investigation.

©2021 American Association for Cancer Research.

Publication Types